Free Trial

Akebia Therapeutics (AKBA) to Release Earnings on Thursday

Akebia Therapeutics logo with Medical background

Key Points

  • Akebia Therapeutics is set to release its Q2 2025 earnings report on August 7th, with analysts anticipating a loss of ($0.02) per share and revenue of $47.60 million.
  • In its previous earnings report, Akebia exceeded expectations by reporting a profit of $0.03 per share and revenue of $57.34 million.
  • Insider trading activity indicates that key executives have sold shares recently, with CFO Erik Ostrowski decreasing his holdings by 7.58% after selling 41,314 shares.
  • Looking to export and analyze Akebia Therapeutics data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Akebia Therapeutics to post earnings of ($0.02) per share and revenue of $47.60 million for the quarter.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.06. The company had revenue of $57.34 million for the quarter, compared to analysts' expectations of $44.88 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Stock Performance

AKBA stock traded down $0.02 during trading on Tuesday, hitting $3.75. 977,763 shares of the company traded hands, compared to its average volume of 4,101,100. The company has a market cap of $983.59 million, a PE ratio of -17.83 and a beta of 0.96. Akebia Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.08. The stock's 50-day simple moving average is $3.63 and its 200 day simple moving average is $2.66. The company has a debt-to-equity ratio of 1.89, a current ratio of 2.23 and a quick ratio of 2.02.

Insiders Place Their Bets

In other news, CAO Richard C. Malabre sold 15,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $4.01, for a total value of $60,150.00. Following the transaction, the chief accounting officer owned 266,914 shares of the company's stock, valued at $1,070,325.14. This represents a 5.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Erik Ostrowski sold 41,314 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $3.67, for a total value of $151,622.38. Following the completion of the sale, the chief financial officer owned 503,586 shares in the company, valued at $1,848,160.62. This represents a 7.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,648 shares of company stock worth $258,841 in the last three months. 3.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Akebia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Baird Financial Group Inc. increased its holdings in Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock worth $41,000 after purchasing an additional 4,000 shares during the period. AQR Capital Management LLC increased its holdings in Akebia Therapeutics by 13.1% during the 1st quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company's stock worth $340,000 after purchasing an additional 20,499 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Akebia Therapeutics by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company's stock worth $265,000 after purchasing an additional 11,517 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Akebia Therapeutics by 171.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after purchasing an additional 1,722,245 shares during the period. Hedge funds and other institutional investors own 33.92% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wall Street Zen upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 3rd. HC Wainwright assumed coverage on Akebia Therapeutics in a research note on Wednesday, June 4th. They issued a "buy" rating and a $8.00 price target on the stock. Leerink Partners assumed coverage on Akebia Therapeutics in a research note on Monday, April 28th. They issued an "outperform" rating and a $7.00 price target on the stock. Finally, Leerink Partnrs raised Akebia Therapeutics to a "strong-buy" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $6.75.

Check Out Our Latest Report on Akebia Therapeutics

About Akebia Therapeutics

(Get Free Report)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

Featured Articles

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)

Should You Invest $1,000 in Akebia Therapeutics Right Now?

Before you consider Akebia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.

While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines